Ligand Buys XOMA Royalty for $39/Share, Raises 2026 Guidance

What happened

Ligand Pharmaceuticals announced a definitive agreement to acquire XOMA Royalty Corporation for $39 per share in cash, plus a contingent value right (CVR), in a deal described as highly complementary to its royalty aggregation model. Management simultaneously raised 2026 guidance and EPS outlook, signaling confidence that the acquisition will accelerate royalty revenue growth beyond the previously guided $200M–$225M range. However, the transaction uses a significant portion of Ligand's deployable capital, consuming cash that could have been allocated to more diversified investments. The increased guidance may partially reflect the acquired royalties, but also raises the bar for organic growth from key assets like FILSPARI and Ohtuvayre. With the stock trading at ~79x P/E, the market now prices in both the near-term accretion and the successful integration of XOMA's portfolio, leaving limited margin of safety.

Implication

The acquisition should initially be viewed as a positive catalyst that validates Ligand's capital deployment strategy and provides immediate accretion to 2026 royalty revenue. However, investors must critically assess whether the $39/share price (plus CVR) represents disciplined underwriting or an overpayment for XOMA's largely legacy assets. The raised guidance masks the fact that Ligand's core organic growth drivers—FILSPARI and Ohtuvayre—still need to deliver independently, and the additional royalties from XOMA may simply be masking slower underlying momentum. Furthermore, the cash deal draws down Ligand's liquidity, reducing the flexibility to pounce on future opportunistic deals. For long-term holders, the risk-reward tilts negative at current valuations unless XOMA integration clearly adds incremental growth beyond what was already priced in.

Thesis delta

The acquisition of XOMA Royalty accelerates Ligand's redeployment story and raises 2026 guidance, but it also increases concentration risk and dilutes the focus on organic driver validation. The thesis shifts from a 'wait for partner data' stance to a 'wait for integration proof' stance, as the stock now embeds expectations for both organic royalty growth and successful asset absorption. Investors should demand clear evidence that XOMA's portfolio does not cannibalize capital from Ligand's core higher-growth assets and that the deal IRR exceeds Ligand's cost of capital.